November 13, 2019

Catabasis Shares November 2019 Newsletter

Catabasis shares the latest edition of their community newsletter, including information about the role of NF-kB in muscle and an update about edasalonexent in development for the treatment of Duchenne. Click here to download (PDF).

Learn More

November 12, 2019

The Duchenne Registry App is Available Now!

After twelve years of collecting data to advance research for Duchenne, PPMD’s Duchenne Registry is excited to share the new and improved Duchenne Registry Mobile App with our community of patients and caregivers! We believe the app will make…

Learn More

November 12, 2019

Solid Biosciences Provides SGT-001 Program Update

Solid Biosciences Inc. provided a clinical update on SGT-001 and reported that the FDA has notified the company that IGNITE DMD, its Phase I/II study of SGT-001, has been placed on clinical hold. To date,…

Learn More

November 6, 2019

Roche/Genentech Announces Decision to Discontinue Development of RG6206 (RO7239361)

We are disappointed to learn that Roche/Genentech is discontinuing development of their investigational anti-myostatin adnectin RG6206 (RO7239361) for the treatment of Duchenne. According to the company, this decision was based on results from a pre-planned…

Learn More

October 30, 2019

PPMD Launches Interactive Drug Development Pipeline

For over twenty five years, Parent Project Muscular Dystrophy has been committed to exploring and supporting innovative therapeutic possibilities. We take a cutting-edge approach to accelerate finding treatments that will end Duchenne for every single…

Learn More

October 22, 2019

Reveragen Biopharma Receives NIH Ethics Grant to Return Data to Participants in Vamorolone Clinical Trials

The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded an ethics research grant to ReveraGen BioPharma to return patient-level and aggregate data to Duchenne patients and…

Learn More

October 22, 2019

WATCH: DYSTANCE 51, a Phase 2/3 Clinical Trial of Investigational Suvodirsen – Webinar Recording

Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave Life Sciences is a clinical-stage…

Learn More

October 9, 2019

2019 World Muscle Society Update – Day 4

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

October 7, 2019

Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with Vamorolone in Duchenne

Santhera Pharmaceuticals has announced the presentation of data showing continued improvement of muscle function and improved tolerability compared with corticosteroids of 18-month vamorolone treatment in Duchenne. PPMD was an earlier funder of this important research…

Learn More

October 7, 2019

2019 World Muscle Society Update – Days 2 & 3

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More